| |
By analyzing workload split data, your sales and marketing teams can target the right HCPs and patients for your therapies. Discover how OneKey’s tiered estimates of an HCP's practice locations can enhance your growth strategy. 
|
|
|
Did you know Specifica offers standalone antibody discovery campaigns? Specifica delivers dozens of discovery and optimization campaigns annually for biotech and pharma clients. Use our scFv, Fab and VHH platform without royalties or milestones. 
|
|
| By Ayla Ellison In this year's Fierce 50 special report, we are highlighting the innovators and leaders who are shaping the future of healthcare, pharma and biotechnology. This year's honorees demonstrate unwavering dedication and creativity, propelling these industries forward. |
|
|
|
By Angus Liu The Keytruda-beating data from Akeso and Summit’s ivonescimab that oncology industry watchers had been awaiting are here. The China-only data are impressive, signaling the PD-1/VEGF bispecific antibody’s potential as a new standard of care in non-small cell lung cancer. |
By James Waldron The recent decision to merge Genentech’s two cancer departments was made for “scientific reasons,” according to executives. |
By Conor Hale Au revoir, Abiomed. Goodbye, DePuy. Bon voyage, Biosense. So long, Cerenovus. Adios, Ethicon. |
|
Still Time to Shine! Submission deadline for the Fierce Life Sciences Innovation Awards have been extended to September 12. Click to submit your entry and learn more about what winner's will receive. 
|
|
By Fraiser Kansteiner Late Monday, the U.S. House of Representatives voted 306-81 in favor of the BIOSECURE Act, which was introduced in January and seeks to halt federal contracts with five named Chinese life-sci companies: WuXi AppTec, WuXi Biologics, BGI Group, MGI and Complete Genomics. |
By Kevin Dunleavy With a strong track record for identifying diamonds in the rough, Bain Capital Life Sciences (BCLS) has become a powerful force in biotech investing, revealing a fourth fund totaling $3 billion. |
By Angus Liu Gilead Sciences has been looking for a win for Trodelvy after two surprise trial failures earlier this year. But it looks like that win won’t come from a triplet regimen that combines the antibody-drug conjugate with Merck’s Keytruda and chemotherapy in newly diagnosed non-small cell lung cancer. |
By Angus Liu AstraZeneca has used AI to devise a unique biomarker for its Daiichi Sankyo-partnered Dato-DXd, hoping to differentiate the antibody-drug conjugate from competitors while offering an explanation why the TROP2-directed therapy appears to work only in some non-small cell lung cancer patients. |
By Joseph Keenan Two Japanese drugmakers and another in India were hit with Form 483s from the FDA following inspections that uncovered issues ranging from a lack of sanitary procedures to improper data collection and monitoring. |
By Darren Incorvaia Roche’s R&D is moving on up. The pharma giant has opened two new high-rises in Basel, Switzerland, according to a Sept. 10 release. The facility is named the Pharma Research and Early Development (pRED) Center, and houses about 1,000 state-of-the-art laboratory and office workplaces. |
By Andrea Park Madrigal Pharmaceuticals broke new ground earlier this year as its Rezdiffra became the first drug approved by the FDA to treat metabolic dysfunction-associated steatohepatitis. Now, with its first marketing campaign for the drug, the company is hoping to direct patients toward that newly paved pathway. |
Fierce podcasts Don’t miss an episode |
| In this week's episode of "Podnosis," we look at how practice management companies are meeting the evolving needs of healthcare providers. |
|
|---|
|
|
|
Tuesday, September 24, 2024 | 2pm ET / 11am PT The transition from clinical to commercial supply chains is a pivotal challenge for life sciences organizations today. Join us for this important and timely discussion with industry experts for a deep dive into the scaling of logistics operations, and how to successfully navigate the complexities. Register now. 
|
|
Whitepaper Facing roadblocks in drug development? Uncover how phase-appropriate technology transfers can help you navigate challenges and speed up your journey to market. Sponsored by: Veranova |
Survey Discover the latest trends and challenges in transparency operations within the pharmaceutical, medtech, and biotech sectors. Our comprehensive survey reveals critical insights into the maturity and effectiveness of transparency programs. Download this insight brief to learn more. Sponsored by: IQVIA |
Whitepaper Stay ahead in biopharma product logistics with the latest insights on cold, ultra-cold and cryogenic storage solutions. Sponsored by: Cardinal Health™️ 3PL Services |
Whitepaper DSCSA Compliance with a Trusted Partner Sponsored by: BioCare |
Whitepaper We interviewed dozens of biopharma leaders on the critical success factors for building a Best Practice commercial organization. This report shares what we learned. Sponsored by: Blue Matter Consulting |
Whitepaper Finding an effective epilepsy treatment can be arduous. Download this brochure to delve into how IQVIA's expertise and innovative strategic approach can streamline the clinical trial process, helping to get new therapies to patients who need them sooner. Sponsored by: IQVIA |
eBook Start leveraging AI to enhance the patient experience while improving personalization, navigation and adherence with the latest free eBook by RxPx. Sponsored by: RxPx |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
